Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Satellos Bioscience Inc (MSCL.TO)

Satellos Bioscience Inc (MSCL.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Stocks in play: Satellos Bioscience Inc. Baystreet - Tue Feb 24, 9:07AM CST

Will present two oral scientific presentations and three posters at the 2026 Muscular Dystrophy Association ...

MSCL.TO : 17.01 (+4.23%)
Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference Business Wire - Tue Feb 24, 6:00AM CST

Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases,...

MSLE : 12.35 (+5.92%)
MSCL.TO : 17.01 (+4.23%)
Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy Business Wire - Wed Feb 18, 6:00AM CST

Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle...

MSLE : 12.35 (+5.92%)
MSCL.TO : 17.01 (+4.23%)
Satellos to Participate in Upcoming Investor Conferences Business Wire - Tue Feb 17, 6:00AM CST

Satellos Bioscience Inc. (Nasdaq: MSLE , TSX: MSCL ) (“Satellos” or the “Company”), a clinical-stage biotechnology company focused on restoring natural muscle...

MSLE : 12.35 (+5.92%)
MSCL.TO : 17.01 (+4.23%)
Stocks in play: Satellos Bioscience Inc. Baystreet - Thu Feb 12, 9:21AM CST

Today announced that the first participant has been dosed in BASECAMP, a three-month, randomized, double-blind, ...

MSCL.TO : 17.01 (+4.23%)
Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy Business Wire - Thu Feb 12, 6:00AM CST

BASECAMP, a three-month, randomized, double-blind, placebo-controlled study, will evaluate SAT-3247’s safety and tolerability, and effect on muscle force, muscle quality and muscle regeneration

MSCLF : 0.9230 (+1.41%)
MSCL.TO : 17.01 (+4.23%)
Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Business Wire - Tue Feb 10, 6:00AM CST

Satellos Bioscience Inc. (Nasdaq: MSLE , TSX: MSCL ) (“Satellos” or the “Company”), a clinical-stage biotechnology company focused on restoring natural muscle...

MSLE : 12.35 (+5.92%)
MSCL.TO : 17.01 (+4.23%)
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares Business Wire - Mon Feb 9, 4:00PM CST

Satellos Bioscience Inc . (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle...

MSLE : 12.35 (+5.92%)
MSCL.TO : 17.01 (+4.23%)
Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States Business Wire - Fri Feb 6, 7:30AM CST

BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS ON SEDAR+

MSLE : 12.35 (+5.92%)
MSCL.TO : 17.01 (+4.23%)
Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq Business Wire - Thu Feb 5, 3:20PM CST

BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS ON SEDAR+

MSCLF : 0.9230 (+1.41%)
MSCL.TO : 17.01 (+4.23%)

Barchart Exclusives

The Saturday Spread: Using an Overlooked Indicator to Assess True Market Risk Barchart - Sat Feb 28, 9:08PM CST
While unusual options activity may be the dominant screener in the options world, volatility skew deserves some love due to its structural intelligence. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot